DENVER, Colo., Nov 7, 2023 (www.247marketnews.com)- Senti Biosciences Inc. (NASDAQ: SNTI) stated, after yesterday’s market close, that it entered a new strategic collaboration with Celest Therapeutics, a China-based biotechnology company, for the clinical development of SENTI-301A to treat solid tumors in China.
Celest will lead clinical development, with technical support from Senti Bio, with the first patient expected to be enrolled in China in the first half of 2024, while Senti Bio is eligible to receive up to $156 million in milestones and royalties from the deal.
Senti Biosciences is trading at $0.5903, up $0.2983 (+102.16%) on 16.3M premarket shares.
Its 52-week range is $0.2701 to $2.75. It set a new 52-week low late October, but bounced well off of that level. It attempted to fight through significant resistance around the 70-cent level for much of this morning’s premarket and, if it can break through that, on strong volume, in the regular session, it could take a shot at the dollar range.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
